

BAFNA PHARMACEUTICALS LTD

CIN: L24294TN1995PLC030698

Corporate Office and Registered Office: Bafna Towers, New No. 68, Old No 299, Tambu Chetty Street, Chennai-600001 (Tamil Nadu)

Email : cs@bafnapharma.com, Web : www.bafnapharma.com

Statement of Unaudited Financial Results for the Nine Months and Quarter Ended 31st December 2022

(₹ in Lakhs except as Stated)

Particulars	Quarter Ended			Period Ended		Year Ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
	(Unaudited)					(Audited)
1 Income from Operations						
(a) Net sales/income from operations	3,421.84	2,196.08	2,046.01	7,310.61	7,015.79	8,514.03
(b) Other Income	141.27	64.22	48.73	335.63	83.37	210.21
2 Total Income	3,563.11	2,260.30	2,094.74	7,646.24	7,099.16	8,724.24
Expenses						
(a) Cost of Raw Material Consumed	2,309.53	1,586.25	1,030.14	4,955.27	4,233.65	5,305.99
(b) Purchase of Stock- In-Trade	346.98	-	-	346.98	-	-
(b) Changes in Inventories of Finished Goods, Work in progress and Stock in trade	(205.17)	(207.46)	207.77	(427.07)	(69.88)	(177.40)
(c) Employee benefits expense	391.68	373.56	363.46	1,115.44	1,079.33	1,450.39
(d) Depreciation and amortisation expense	139.84	112.44	120.83	380.92	409.20	549.33
(e) Finance costs	57.07	45.04	41.10	133.35	62.62	79.38
(f) Other expenses	223.69	189.58	161.15	544.74	571.10	785.79
3 Total expenses	3,263.62	2,099.41	1,924.45	7,049.63	6,286.02	7,993.48
4 Profit before tax and Exceptional Items	299.49	160.89	170.29	596.61	813.14	730.76
5 Exceptional Items					196.53	215.65
6 Net Profit before Tax (4-5)	299.49	160.89	170.29	596.61	616.60	515.11
7 Tax expense						
- Current Tax	-	-	-	-	-	-
- Deferred Tax	-	-	-	-	-	-
8 Net Profit after Tax (6-7)	299.49	160.89	170.29	596.61	616.60	515.11
9 Other Comprehensive income	(0.60)	(0.60)		(1.80)	(13.06)	(2.40)
10 Total comprehensive income for the period	298.89	160.29	170.29	594.81	603.55	512.71
11 Paid up Share Capital (Face Value of ₹ 10 each)	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
Earnings per Equity share						
Equity shares of par value Rs. 10 each						
(a) Basic	1.26	0.68	0.72	2.51	2.55	2.17
(b) Diluted	1.26	0.68	0.72	2.51	2.55	2.17

Notes

- The above unaudited financial results for the quarter and Nine Months ended 31st December 2022, have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on 08.02.2023. The Statutory Auditors has conducted a "Limited Review" of these financial results in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- The Figures for the quarter ended 31st December 2022 & preceding quarter ended 31st December 2021 are the balancing figures between the unaudited year to date figures for Nine Months period ended 31st December and the unaudited published figures for the six months ended 30th September of the respective financial years. The figures for the corresponding previous periods have been regrouped and reclassified wherever necessary, to make them comparable
- The above results have been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- Company's business relates to the manufacturing of pharmaceuticals formations, which in context of Indian Accounting Standards 108 (Ind AS 108) as notified under Section 133 of the Companies Act, 2013 is considered as the only segment.

For Bafna Pharmaceuticals Limited



P. Hemalatha

Executive Director
(DIN: 02714329)

Place : Chennai
Date : 08.02.2023